Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Hims & Hers Health announced a partnership with Eli Lilly to sell the drugmaker's FDA-approved obesity medicines directly through the telehealth platform's website. The agreement, described by analysts as both surprising and inevitable, sent Hims & Hers shares surging on the day of the announcement.
Epilogue added 5d ago, after coverage quieted.
The brief
According to Reuters, Eli Lilly announced a partnership on Friday allowing Hims & Hers Health to offer its obesity medications Zepbound and Foundayo directly on the telehealth platform. Previously, patients could only access Lilly drugs on Hims & Hers by leaving the site and visiting Lilly's own cash-pay platform, LillyDirect. Reuters reported that this move sent the telehealth company's shares up by more than 7% in premarket trading. MarketWatch and Investor's Business Daily also noted the stock rally following the GLP-1 deal. This agreement aligns Lilly with its Danish rival Novo Nordisk, which has been selling Wegovy and Ozempic through Hims & Hers since March after previously suing the telehealth company over compounded versions. Leerink Partners analyst Michael Cherny called the Lilly partnership a clear positive, noting to Reuters that the deal completes Hims & Hers' process to secure access to the two leading GLP-1 drugmakers following its exit from mass compounding. Ilya Yuffa, president of Lilly USA, told Reuters that previously the ease and ability for someone on the platform to get Lilly medicine was not fully straightforward. Yuffa stated that any friction point for consumers increases the chance of abandonment. As part of the agreement, Yuffa told Reuters that Hims & Hers has agreed to stop selling any compounded versions or knockoffs of Lilly's obesity medications. Self-pay pricing starts at $299 per month for the injectable GLP-1 Zepbound and $149 per month for the oral Foundayo, matching prices on LillyDirect. Reuters reported that Novo's drugs on the platform start at $199 per month for the Wegovy injector pen and $149 per month for the Wegovy pill. According to Lilly, roughly 40% to 45% of Zepbound sales go through self-pay channels. Analysts told Reuters that Hims & Hers could receive a boost next year if employers drop weight-loss drug coverage to cut costs. Reuters noted that Lilly recently raised its full-year revenue forecast by $5 billion due to booming demand for its injectable weight-loss treatments, driving the company to a $1.2 trillion market valuation.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6d ago.
Quick answers
What drugs are included in the Hims & Hers and Eli Lilly deal?
The deal includes Eli Lilly's injectable Zepbound and its oral Foundayo.
How much do Lilly's obesity drugs cost on the Hims & Hers platform?
Self-pay pricing starts at $299 per month for Zepbound and $149 per month for Foundayo.
What did Hims & Hers agree to stop selling as part of the agreement?
Hims & Hers agreed not to sell any compounded versions or knockoffs of Lilly's obesity medications.
Coverage (12)
- LifeMD Adds Mail-Order Option for Lilly’s Zepbound and Foundayo www.tokenpost.com · 9d ago
- Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal? Simply Wall St · 9d ago
- Eli Lilly, Hims & Hers reach deal on direct obesity drug sales qz.com · 9d ago
- Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement Barron's · 9d ago
- Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs Fierce Healthcare · 9d ago
- Lilly turns to Hims & Hers to boost access to obesity drugs in US FirstWord Pharma · 9d ago
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines PR Newswire · 9d ago
- Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients Bloomberg.com · 9d ago
- Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. MarketWatch · 9d ago
- Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines Hims & Hers Newsroom · 9d ago
- Lilly to sell obesity drugs directly on Hims & Hers site Reuters · 9d ago
- Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly Investor's Business Daily · 9d ago
Topics
Related trends
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New research outlines five evidence-based strategies to maintain weight loss after discontinuing GLP-1 medications like semaglutide and tirzepatide.
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
Makers of obesity drugs hit back at claims of negative side effects
Makers of blockbuster weight loss drugs defend product safety amid mounting scrutiny over potential side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.